Investigational drug · Phase 2
TE-8105 MAD
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Overweight and Obesity.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "TE-8105 MAD"
First trial start
2024
Jul 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TE-8105 MAD", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight and Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "TE-8105 MAD" as an intervention, largest first.
- A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity ParticipantsPivotal-lookingNot yet recruiting
Immunwork, Inc.Industry
NCT07857473 · 204 participants (planned) · Start Oct 2026 · Primary completion Feb 2028
Drug: TE-8105 MAD Cohort 1; TE-8105 MAD Cohort 2 and 2 more · For: Overweight and Obesity
Sites: Leichhardt, Australia; Penrith, Australia
Immunwork, Inc.Industry
NCT06471530 · 38 participants · Start Jul 9, 2024 · Primary completion Jan 3, 2025
Drug: TE-8105 SAD Cohort 1; TE-8105 SAD Cohort 3 and 5 more · For: Overweight and Obesity
Sites: Adelaide, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Overweight and Obesity
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- MazdutideLY3305677Phase 35 trials
Eli Lilly · Type 2 Diabetes, Obesity, Overweight
- HDM1002Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight and Obesity
- DA-302168SPhase 33 trials
Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus
- AZD9550Phase 23 trials
AstraZeneca · Overweight and Obesity, Obesity/Overweight, Obesity or Overweight
- CPX101Phase 21 trial
Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. · Overweight and Obesity
- WVE-007Phase 21 trial
Wave Life Sciences USA, Inc. · Overweight and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.